What Rapiscan contains
The active substance in Rapiscan is regadenoson. Each 5 ml vial of Rapiscan contains 400 micrograms of regadenoson.
The other ingredients are: disodium edetate, disodium phosphate dihydrate, sodium dihydrogen phosphate monohydrate, propylene glycol, water for injections.
What Rapiscan looks like and contents of the pack
Rapiscan solution for injection is a clear, colourless solution with no particles visible. Rapiscan is supplied in a carton containing a single use 5 ml glass vial with a rubber stopper and aluminium sealed cap.
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder:
Rapidscan Pharma Solutions EU Ltd.
Regent?s Place
338 Euston Road
London NW1 3BT
United Kingdom
Manufacturer:
Gilead Sciences Limited
IDA Business & Technology Park
Carrigtohill
County Cork
Ireland
This leaflet was last approved in
The following information is intended for medical or healthcare professionals only:
Rapiscan should be administered as a rapid, 10-second injection into a peripheral vein using a 22-gauge or larger catheter or needle.
5 ml of sodium chloride 9 mg/ml (0.9%) solution for injection should be administered immediately after the injection of Rapiscan.
The radiopharmaceutical for the myocardial perfusion imaging agent should be administered 10-20 seconds after the sodium chloride 9 mg/ml (0.9%) solution for injection. The radiopharmaceutical may be injected directly into the same catheter as Rapiscan.
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.
This medicinal product should be inspected visually for particulate matter and discolouration prior to administration.
Any unused product or waste material should be disposed of in accordance with local requirements.
For further information, please refer to the complete Summary of Product Characteristics enclosed with the pack.